0.05Open0.05Pre Close0 Volume2 Open Interest25.00Strike Price0.00Turnover220.69%IV156.66%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier15DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0333Delta0.0167Gamma195.20Leverage Ratio-0.0101Theta0.0001Rho6.50Eff Leverage0.0015Vega
Stoke Therapeutics Stock Discussion
Stoke Therapeutics Taps Former Vertex COO as Interim CEO Amid Breakthrough Drug Progress
Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome
No comment yet